Keywords

antiplatelet therapy, clopidogrel, clopidogrel resistance, cyclopentyl-triazolo-pyrimidine agents, CYP2C19 genetic variance, DAPT, dual antiplatelet therapy, oral antiplatelet comparison, oral antiplatelets, prasugrel, protease-activated receptor-1 antagonists, thienopyridines, ticagrelor, vorapaxar

Authors

1. Jeffords, Travis BSN-RN, CCRN

Abstract

Abstract: New and more potent oral antiplatelet agents have shown better clinical outcomes over the last few years. This article reviews the latest oral antiplatelet therapies available, their indications and contraindications, genetic resistance, and major drug interactions.